StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $4.00 | $4.09 | +2.25% | 1.8M |
| 05-12 | $4.08 | $4.13 | +1.23% | 0.9M |
| 05-13 | $4.09 | $4.10 | +0.24% | 0.8M |
| 05-14 | $4.14 | $3.89 | -6.04% | 3.6M |
| 05-15 | $3.85 | $3.58 | -7.01% | 3.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for LRMR.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q1 2020 2020-03-31 | Annual 2019 2019-12-31 | Annual 2019 2019-09-30 | Annual 2019 2019-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-6.67M | $-23.21M | $-17.06M | $-8.43M |
Net Income | $-6.67M | $-23.13M | $-17.06M | $-3.70M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $73.70M | $5.20M | $92.89M | $103.88M |
Total Liabilities | $22.96M | $5.89M | $33.01M | $31.75M |
Cash & Equivalents | $38.98M | $1.01M | $43.34M | $37.24M |
Free Cash Flow OCF − CapEx | $-8.98M | $-22.78M | $-14.82M | $-9.00M |
Shares Outstanding | 37.47M | 6.09M | 37.37M | 37.33M |
Fundamentals not available for LRMR.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.